By targeting IL-6, TCZ not only reduces systemic inflammation but also influences key mediators of cardiovascular risk, such as endothelial dysfunction, monocyte activity, neutrophil extracellular trap (NET) formation (NETosis), and oxidative stress – principal drivers of atherosclerosis and CVD. This evidence concerns the gene IL6 and atherosclerosis.